Sarepta Therapeutics - formerly AVI BioPharma - remains focused on developing first-in-class, RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Sarepta's unique technology has yielded a diverse pipeline of RNA-based therapeutics that include our lead clinical candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy, a debilitating and life-threatening genetic disorder, as well as potential treatments for some of the world's most lethal infectious diseases.
Our exceptional science- and commercialization-focused team is committed to realizing our vision of becoming a leading, independent biotechnology company dedicated to translating our RNA-based science into transformational therapeutics and, most importantly, bringing these novel therapeutics to patients who have no other options.
AVI BioPharma, Inc., a biopharmaceutical company, develops therapeutic products principally based on NEUGENE antisense technology. It offers various drugs for the treatment of cardiovascular diseases, infectious diseases, cancer, and polycystic kidney diseases, as well as for regulating drug metabolism. The company has collaboration agreement with Chiron Corporation for research, development, and commercialization of antisense therapeutics against hepatitis C virus; Cook Group Incorporated for the development and commercialization of products for vascular diseases; and Ercole Biotech, Inc. to identify and develop drugs that direct the splicing of messenger RNA to treat a range of genetic and acquired diseases. AVI BioPharma was founded in 1980 and is based in Portland, Oregon.
|Form Type ||Received ||Period Ending ||Size ||Report |
|PRE 14A ||May 16, 2016 ||Jun 27, 2016 ||2.7 MB || PDF RTF HTML XLS |
|SC 13G ||May 6, 2016 || ||14.4 KB || PDF RTF HTML XLS |
|8-K ||May 5, 2016 ||May 5, 2016 ||72.4 KB || PDF RTF HTML XLS |
|10-Q ||May 5, 2016 ||Mar 31, 2016 ||5.0 MB || PDF RTF HTML XLS |
|10-K/A ||Apr 29, 2016 ||Dec 31, 2015 ||2.0 MB || PDF RTF HTML XLS |
|4 ||Apr 22, 2016 ||Apr 20, 2016 ||5.0 KB || PDF RTF HTML XLS |
|4 ||Mar 17, 2016 ||Mar 14, 2016 ||7.4 KB || PDF RTF HTML XLS |
|4 ||Mar 17, 2016 ||Mar 14, 2016 ||5.2 KB || PDF RTF HTML XLS |
|4 ||Mar 17, 2016 ||Mar 14, 2016 ||4.7 KB || PDF RTF HTML XLS |
|8-K ||Mar 8, 2016 ||Mar 7, 2016 ||30.8 KB || PDF RTF HTML XLS |
Phone and email address..................Lead investigator in the DMD trial.....London College of Medicine
•The Board Monitor and The Board Assistants herewith, Are not licensed brokers and assume NO Responsibility for the Actions,
Investment decisions, and or Messages Posted on this Forum.
•We do NOT recommend that Anyone Buy or Sell any Securities Posted Herewith.
Any Trade entered into Risks the Possibility of Losing the Funds Invested.
•There are NO Guarantees when Buying or Selling Any Security.